A Urinary Peptide Biomarker Panel to Identify Significant Prostate Cancer
BAUS ePoster online library. Salji M. 06/30/16; 132023; P11-8 Disclosure(s): Movember GAP1 Urinary Biomarker Consortium
Mr. Mark Salji
Mr. Mark Salji
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)
P11-8

Background: Urinary biomarkers which can identify patients with significant prostate cancer (PC) used as an adjunct to PSA testing is an attractive clinical prospect. Capillary electrophoresis coupled to mass spectrometry (CE-MS) is a tool for the discovery of such potential urinary peptide biomarkers.

Methodology: CE-MS was performed on 313 samples of urine obtained from patients with significant PC with Gleason 8-10 or T3/4 disease (n=66) and controls with High Grade -PIN, low volume low grade Gleason 6 disease, Prostatitis, BPH or normal histology (n=247). An initial training set of 236 patients was used to identify a biomarker panel separating controls (n=188) from significant PC (n=48). Performance was then compared to PSA by ROC analysis in a clinical test set (n=77, 18 cases and 59 controls) classified by PSA.

Results: A panel of 94 peptides were identified in the training cohort separating significant PC and controls (p<0.05, using Benjamini and Hochberg adjustment and bootstrapping cross validation). ROC analysis showed an AUC=0.82 for our biomarker panel in the training cohort. As expected the AUC for PSA in the test cohort was almost perfect (0.968) as it was classified by PSA. Our biomarker panel showed AUC of 0.69 in the test cohort which significantly differed from PSA (p<0.001).

Conclusions: Using CE-MS we have generated a 94 peptide urine biomarker panel specifically to identify significant PC from insignificant disease. Our biomarker panel shows differing ROC to PSA in an independent PSA classified test cohort and may provide a useful adjunct to PSA testing.

P11-8

Background: Urinary biomarkers which can identify patients with significant prostate cancer (PC) used as an adjunct to PSA testing is an attractive clinical prospect. Capillary electrophoresis coupled to mass spectrometry (CE-MS) is a tool for the discovery of such potential urinary peptide biomarkers.

Methodology: CE-MS was performed on 313 samples of urine obtained from patients with significant PC with Gleason 8-10 or T3/4 disease (n=66) and controls with High Grade -PIN, low volume low grade Gleason 6 disease, Prostatitis, BPH or normal histology (n=247). An initial training set of 236 patients was used to identify a biomarker panel separating controls (n=188) from significant PC (n=48). Performance was then compared to PSA by ROC analysis in a clinical test set (n=77, 18 cases and 59 controls) classified by PSA.

Results: A panel of 94 peptides were identified in the training cohort separating significant PC and controls (p<0.05, using Benjamini and Hochberg adjustment and bootstrapping cross validation). ROC analysis showed an AUC=0.82 for our biomarker panel in the training cohort. As expected the AUC for PSA in the test cohort was almost perfect (0.968) as it was classified by PSA. Our biomarker panel showed AUC of 0.69 in the test cohort which significantly differed from PSA (p<0.001).

Conclusions: Using CE-MS we have generated a 94 peptide urine biomarker panel specifically to identify significant PC from insignificant disease. Our biomarker panel shows differing ROC to PSA in an independent PSA classified test cohort and may provide a useful adjunct to PSA testing.

Code of conduct/disclaimer available in General Terms & Conditions

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies